Shock
Drug research and approvals for shock: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 18, 2026, 389 studies of shock are recruiting on ClinicalTrials.gov, Health Canada has authorized 7 drug trials for it since 2013, FDA has 0 approved and 4 open orphan designations naming it, and the EU has 1 authorised medicine for it.
- Recruiting worldwide: 389
- Trials authorized in Canada: 7
- FDA orphan approvals: 0
- EU medicines: 1
Recruiting now
Newest start dates first, of 389 recruiting on ClinicalTrials.gov ↗- Clinical Value of EMR3 in Sepsis Diagnosis, Monitoring, and Prognosis: A Multicenter Prospective Observational StudyNCT07896018 · Not reported · Sir Run Run Shaw Hospital · starts Nov 1, 2026
- Dynamic SvO2 in Predicting Fluid Responsiveness in Septic ShockNCT07516236 · Not reported · Menoufia University · starts Nov 1, 2026
- Dopamine vs. Norepinephrine for Hypotension in Neonates With Pulmonary Hypertension (DONE)NCT07322133 · Phase 4 · University of California, Davis · starts Oct 30, 2026
- Immunothrombosis With Septic Shock Undergoing Renal Replacement Therapy With the OXIRIS MembraneNCT06440317 · Not reported · University Hospital, Bordeaux · starts Oct 22, 2026
- Shock Wave Therapy Versus High-Intensity Laser Therapy for Coccydynia (Tailbone Pain)NCT07898514 · Not applicable · Ahmet Sümen · starts Oct 16, 2026
- A Trial of Adjunctive Fludrocortisone (50mcg, 100mcg or Placebo) in Critically Ill Patients With Septic Shock Receiving…NCT07898462 · Phase 3 · The George Institute · starts Oct 16, 2026
- CRP Apheresis in Infarct-Related Cardiogenic ShockNCT07687017 · Not applicable · Leipzig Heart Science gGmbH · starts Oct 16, 2026
- Comparison of Cardiac Index Measurement Using Right Ventricular Pressure Curve Analysis and Thermodilution Via a…NCT07628023 · Not reported · Assistance Publique - Hôpitaux de Paris · starts Oct 15, 2026
- INitiation and Titration of Guideline Directed Medical TheRApy in HearT Failure Cardiogenic Shock With ImpElla 5.5 for…NCT06965504 · Not applicable · Abiomed Inc. · starts Oct 2, 2026
- Predictors of In-Hospital Mortality in Severe Abdominal TraumaNCT07843628 · Not reported · Minia University · starts Oct 1, 2026
Drug pipeline
1 approved, 13 in phase 3, 8 in phase 2, 3 in phase 1 or earlier; from ChEMBL's drug indications, furthest stage reached for this conditionApproved: Angiotensin ii
- Norepinephrine
- Phase 3 Adrenergic receptor agonist
- Vasopressin
- Phase 3 Vasopressin receptor agonist
- Tranexamic acid
- Phase 3 Plasminogen inhibitor
- Levosimendan
- Phase 3 Phosphodiesterase 3 inhibitor
- Centhaquine
- Phase 3
- Dopamine
- Phase 3 Beta-1 adrenergic receptor agonist
- Empagliflozin
- Phase 3 Sodium/glucose cotransporter 2 inhibitor
- Tilarginine
- Phase 3 Nitric oxide synthase inhibitor
- Fibrinogen, human
- Phase 3 Fibrinogen exogenous protein
- Oxygen
- Phase 3 Essential for cellular homeostasis
- Dextran 70
- Phase 3
- Blood, whole
- Phase 3
- Dobutamine
- Phase 2 Beta-1 adrenergic receptor agonist
- Heparin
- Phase 2 Antithrombin-III activator
- Istaroxime
- Phase 2 Sodium/potassium-transporting ATPase inhibitor
- Nitroglycerin
- Phase 2 Soluble guanylate cyclase activator
- Estrogens, conjugated
- Phase 2 Estrogen receptor agonist
- Epinephrine
- Phase 2 Adrenergic receptor agonist
- Albumin human
- Phase 2 Bilirubin sequestering agent
- Ascorbic acid
- Phase 2 Supplement
- Valproic acid
- Phase 1 Succinate semialdehyde dehydrogenase inhibitor
- Propofol
- Phase 1 GABA-A receptor; anion channel positive allosteric modulator
- Aluminum hydroxide
- Phase 1 Antacid
How its trials ended
952 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 192 whose ending is known, 30% met their primary endpoint, 21% missed it and 49% stopped early.
- Completed, result not reported33235%
- Ongoing21923%
- Status unknown20922%
- Met its primary endpoint576%
- Stopped: other or unclear475%
- Missed its primary endpoint414%
- Stopped: enrollment or feasibility263%
- Stopped: lack of efficacy101%
- Stopped: funding51%
- Stopped: sponsor or business decision40%
- Stopped: safety20%
Trials authorized in Canada
Newest first; search them all in Canada trials| Dec 15, 2025 | Beta-blocker therapy versus standard care in patients with septic shock: a pilot randomized controlled trial utilizing predictive enrichment with point-of-care…Esmolol | London Health Sciences Centre | Ongoing |
| Dec 17, 2024 | Adjunctive methylene blue in septic shock (BLUSH): a pilot randomized controlled trialMethylene blue | Dr Shannon Mario Fernando | Pending |
| Feb 24, 2022 | Umbilical mesenchymal stromal cells as cellular immunotherapy for septic shock (uc-ciss ii): a multi-center, double-blind, phase II randomized controlled trialAllogenic umbilical cord mesenchymal stromal cells (uc-mscs) | Ottawa Hospital Research Institute | Ongoing |
| Apr 26, 2021 | Pragmatic pediatric trial of balanced versus normal saline fluids in sepsis (prompt bolus)Plasma-lyte a/ Lactated ringer's/ Sodium chloride | Governors of The University of Calgary | Ongoing |
| Aug 3, 2017 | Heparin anticoagulation to improve outcomes in septic shock: the halo international phase II rctHeparin sodium | University of Manitoba | Ongoing |
| Apr 1, 2015 | Treatment of septic shock by inhibiting autodigestion and preserving gut integrity with enteric LB1148 (ssail study)LB1148 (tranexamic acid) | Leading Biosciences Inc | Ongoing |
| Dec 19, 2014 | Cellular immunotherapy for septic shock (CISS)Allogeneic mesenchymal stromal cells (MSCS) | Ottawa Hospital Research Institute | Ongoing |
FDA orphan designations
Approved first, then open designations, newest first| Aug 6, 2013 | Conjugate of a dengue virus specific small chemical ligand…Treatment of dengue fever (includes dengue hemorrhagic fever and dengue shock syndrome) | NanoViricides Incorporated | Designated |
| Dec 18, 2007 | Hemoximer (pyridoxalated hemoglobin polyoxyethylene)Treatment of cardiogenic shock | Apex Bioscience, Inc. | Designated |
| Apr 11, 2005 | Tilarginine acetateTreatment of cardiogenic shock | Arginox Pharmceuticals, Inc. | Designated |
| Nov 4, 1985 | Monoclonal antiendotoxin antibody XMMEn-0e5Treatment of patients with gram-negative sepsis which has progressed to shock. | Pfizer, Inc. | Designated |
Medicines authorised in the EU
Newest first| Authorised | Medicine | Holder | EPAR |
|---|---|---|---|
| Aug 23, 2019 | GiaprezaAngiotensin II | Paion Pharma GmbH | EMA ↗ |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA